Immuneering Corporation
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Immuneering Corporation's yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 91% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
- Tangible Net Worth Ratio: Of every $100 of net worth, $97 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 85% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-262.0×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 91% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 100%
Sales fell 100% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-100% / +90%In 3 years sales changed by -100% while total assets changed by +90%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-114.2×Operating cash was negative last year, while some debt falls due within a year.
Lower than 85% of Healthcare companies in United States.
Cash Cushion Ratio
+69%Cash, after subtracting all debt, equals 69% of its market value (net cash).
Higher than 82% of Healthcare companies in United States.
Tangible Assets Ratio
97%Of every $100 the company owns, $97 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 80% of Healthcare companies in United States.
Tangible Net Worth Ratio
97%Of every $100 of net worth, $97 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 85% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Immuneering Corporation made a loss over the last year. Immuneering Corporation owes $0.06 for every $1 it owns. Immuneering Corporation made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossImmuneering Corporation made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.29The share price is 1.29 times Immuneering Corporation's book value per share, lower than 73% of Healthcare companies in United States.
Market cap
$246 MThe total market value of all of Immuneering Corporation's shares at today's price (share price × number of shares), smaller than 55% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$191 MWhat Immuneering Corporation would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.95Net worth divided by the number of shares. The share price of $3.81 is 1.3 times this, which is the P/B above.
Return on equity (ROE)
-52.1%Immuneering Corporation lost 52.1% of its shareholders' money over the last year, lower than 52% of Healthcare companies in United States.
Owes vs Owns
0.06×Immuneering Corporation owes $0.06 for every $1 it owns (low), lower than 95% of Healthcare companies in United States.
Dividend yield
NoneImmuneering Corporation does not currently pay a dividend.
Profit growth
LossImmuneering Corporation made a loss in each of the last two years.
Cash vs debt
Net cashImmuneering Corporation held $169 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Immuneering Corporation: $246 M ÷ $191 M (30 Jun 2026) = 1.3.
What is Immuneering Corporation's return on equity?
Immuneering Corporation lost 52.1% of its shareholders' money over the last year, lower than 52% of Healthcare companies in United States.
How much does Immuneering Corporation owe compared with what it owns?
Immuneering Corporation owes $0.06 for every $1 it owns (low), lower than 95% of Healthcare companies in United States.
Does Immuneering Corporation pay a dividend?
No. Immuneering Corporation does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.